Sporadic multiple primary melanoma cases:: CDKN2A germline mutations with a founder effect

被引:54
作者
Auroy, S
Avril, MF
Chompret, A
Pham, D
Goldstein, AM
Bianchi-Scarrá, G
Frebourg, T
Joly, P
Spatz, A
Rubino, C
Demenais, F
Bressac-de Paillerets, B
机构
[1] Inst Gustave Roussy, Serv Genet, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Serv Dermatol, F-94805 Villejuif, France
[3] NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA
[4] Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy
[5] IFMRP, INSERM EP19906, Fac Med & Pharm, Rouen, France
[6] CHU Charles Nicolle, Serv Dermatol, Rouen, France
[7] Inst Gustave Roussy, Dept Anatomopathol, Villejuif, France
[8] Hop St Louis, INSERM EPI 00 06, Paris, France
关键词
D O I
10.1002/gcc.1183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple primary cancers are one of the hallmarks of inherited predisposition. Outside the familial context, multiple primary tumors could be related either to germline de novo mutations or to low-penetrance mutations, in predisposing genes. We selected 100 patients who displayed multiple primary melanoma (MPM) without any known melanoma cases recorded within their families and looked for germline mutations in the two melanoma-predisposing genes identified to date, CDKN2A and CDK4 exon 2. Nine patients (9%) had germline mutations in CDKN2A, whereas none carried germline mutations in exon 2 of CDK4. Seven cases displayed a recurrent missense mutation, G101W, already described in more than 20 melanoma-prone families; one case carried a missense mutation never reported to date (PI 14S), and the last case was a carrier of a 6 bp insertion at nucleotide 57 resulting in a duplication of codons 18 and 19. To ascertain whether the G101W was a mutational hot spot for de novo mutations or a common founder mutation, we genotyped eight microsatellite markers flanking the CDKN2A gene. After allowing for recombination over time, haplotype sharing provided evidence for an original G101W mutation common to 6 out of 7 sporadic MPM cases. Therefore, it can be concluded that de novo germline CDKN2A mutations associated with MPM are rare. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:195 / 202
页数:8
相关论文
共 42 条
[1]   Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma [J].
Arap, W ;
Knudsen, ES ;
Wang, JYJ ;
Cavenee, WK ;
Huang, HJS .
ONCOGENE, 1997, 14 (05) :603-609
[2]   Tumor suppressor p16INK4A:: Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4 [J].
Byeon, IJL ;
Li, JN ;
Ericson, K ;
Selby, TL ;
Tevelev, A ;
Kim, HJ ;
O'Maille, P ;
Tsai, MD .
MOLECULAR CELL, 1998, 1 (03) :421-431
[3]  
CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041
[4]   GENETIC ASPECTS OF MALIGNANT MELANOMA [J].
CAWLEY, EP .
AMA ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1952, 65 (04) :440-450
[5]   A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families [J].
Ciotti, P ;
Struewing, JP ;
Mantelli, M ;
Chompret, A ;
Avril, MF ;
Santi, PL ;
Tucker, MA ;
Bianchi-Scarrà, G ;
Bressac-de Paillerets, B ;
Goldstein, AM .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (02) :311-319
[6]  
*DIR GEN SANT RES, 1998, CANC FRANC INC MORT, P70
[7]  
Ghiorzo P, 1999, INT J CANCER, V83, P441, DOI 10.1002/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO
[8]  
2-R
[9]   On the black-hole kink [J].
GonzalezDiaz, PF .
INTERNATIONAL JOURNAL OF MODERN PHYSICS D, 1997, 6 (01) :57-68
[10]  
Greene MH, 1979, HUMAN MALIGNANT MELA, P139